New directions for drug-resistant breast cancer: the CDK4/6 inhibitors

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

(2014) RS Finn et al.   CANCER RESEARCH

Aromatase inhibitors in the breast cancer clinic: focus on exemestane

(2014) Kathleen Van Asten et al.   ENDOCRINE-RELATED CANCER

Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma

(2013) J. Rader et al.   CLINICAL CANCER RESEARCH

Bisphosphonate-Related Osteonecrosis of Jaw in the Adjuvant Breast Cancer Setting: Risks and Perspective

(2013) Charles L. Shapiro   JOURNAL OF CLINICAL ONCOLOGY

Use of SERMs for treatment in postmenopausal women

(2013) JoAnn V. Pinkerton et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

(2012) Rita S. Mehta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whether to target single or multiple CDKs for therapy? That is the question

(2010) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Third-Generation SERMs May Face Uphill Battle

(2010) C. Schmidt   JNCI-Journal of the National Cancer Institute

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

CDK inhibitors in cancer therapy: what is next?

(2007) Marcos Malumbres et al.   TRENDS IN PHARMACOLOGICAL SCIENCES